MA-QUANTIS
Quantis, a BCG company and leading global sustainability consultancy driving sustainable transformation to align businesses with planetary boundaries, today released its global food and beverage report, Recipe for Transformation. The report surveyed more than 600 professionals and C-level executives across multiple business functions in the food and beverage industry. Respondents work in large companies within retail, wholesale, consumer packaged goods, commodities and agriculture subsectors of the food and beverage industry.
76% of respondents reported some level of confidence in their sustainability roadmaps and ability to achieve environmental goals by 2030, but action plans are missing critical components for success. Portfolio redesign, regenerative agriculture and plant-based initiatives were cited as the lowest three priorities for the next year, despite having greatest potential for radical transformation. Clear action plans are the second-most important success factor (38%), but they are lacking and 26% of respondents still view them as a challenge.
Other key findings included:
- The supply chain remains the top challenge: 42% of respondents cite its complexities as the largest barrier to success.
- Financial investment remains a barrier, departmental budgets reflect that: Cited as the second largest barrier to success, allocating funds remains a struggle - the average percentage of annual budget allocated to reducing environmental impact is just 12.54 across departments.
- Chief Sustainability Officers need more inter-departmental buy-in: Company commitment and culture set by leadership were the largest drivers of sustainable practices across departments, but the two biggest barriers to success (supply chain and budget allocation) sit largely outside their control.
- Packaging is priority: Most respondents have tools and budget in place to make packaging more sustainable, and 62% cited it as a top priority for the next year – this is a clear starting point across brands, but critical levers for scaling and implementing these efforts are missing.
- Consumers are ready – the industry just needs to deliver: Even in the current economic climate, 100% of marketing respondents have seen changes in consumer behavior regarding sustainable purchasing habits. More than half cite that their customers are more interested in sustainable products and willing to spend more to get them.
“Though food and beverage sector leaders are making progress, the path to alignment with planetary boundaries and resilience will require a shift from sustainability in a silo to sustainability embedded across business functions,” said Charlotte Bande, Global Food & Beverage Lead for Quantis. “Estimates show that food and beverage organizations could lose up to 26% of their value if they don’t act quickly, but much still stands in the way of doing so effectively and efficiently. Securing more budget and driving impactful transformation will require collaboration, both throughout departments internally and with strategic partners across the value chain.”
To download the Global Food Report, Recipe for Transformation, please visit www.quantis.com/Food24. To learn more about Quantis, please visit www.quantis.com.
About Quantis
Quantis, a BCG company, is a global sustainability consultancy pioneering approaches to solve critical environmental challenges. The group partners with leading organizations who are serious about reducing their environmental impacts to future-proof their businesses and prosper in a new planetary economy. Quantis’ unique approach combines deep environmental expertise, strategic business knowledge, and enterprise transformation skills to help organizations shape policies, practices and business models that align with the planet’s capacity while building resilience, unlocking innovation, and optimizing performance. With offices in the US, France, Switzerland, Germany and Italy and clients around the world, Quantis is a key partner in inspiring sustainable change on a global scale.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240530216118/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
